Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1

Conformationally constrained HIV-1 Env and gp120 immunogens induce broadly cross-reactive neutralizing antibodies. Thus, it is now feasible to rationally design an HIV-1 vaccine that affords protection through humoral mechanisms. This paper reviews our progress toward the development of an oral bact...

Full description

Saved in:
Bibliographic Details
Published in:FEMS immunology and medical microbiology 2003-07, Vol.37 (2), p.129-134
Main Authors: Fouts, T.R., DeVico, A.L., Onyabe, D.Y., Shata, M.T., Bagley, K.C., Lewis, G.K., Hone, D.M.
Format: Article
Language:English
Subjects:
Administration, Oral
AIDS Vaccines - immunology
Animals
Bacterial Vaccines - genetics
Bacterial Vaccines - immunology
Biological and medical sciences
Female
Fundamental and applied biological sciences. Psychology
Gene Products, env - genetics
Gene Products, env - immunology
Genetic Vectors
HIV Antibodies - blood
HIV Antibodies - immunology
HIV Envelope Protein gp120 - genetics
HIV Envelope Protein gp120 - immunology
HIV-1 - immunology
Humans
Immunodeficiency virus
Mice
Mice, Inbred BALB C
Microbiology
Mucosal immunity
Neutralization Tests
Salmonella
Salmonella - genetics
Salmonella - immunology
Shigella
Shigella - genetics
Shigella - immunology
Vaccine vector
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conformationally constrained HIV-1 Env and gp120 immunogens induce broadly cross-reactive neutralizing antibodies. Thus, it is now feasible to rationally design an HIV-1 vaccine that affords protection through humoral mechanisms. This paper reviews our progress toward the development of an oral bacterial vaccine vector that is capable of delivering an HIV-1 DNA vaccine to host lymphoid tissues and inducing broadly neutralizing antibodies to HIV-1 in the mucosal and systemic immune compartments.
ISSN:0928-8244
1574-695X
DOI:10.1016/S0928-8244(03)00067-1